Logo Carenity
Logo Carenity
Join now! Log in
flag en
flag fr flag es flag de flag it flag us
Home

Forums

Latest discussions
General discussions
See all - Forum index from A to Z

Conditions

Fact sheets
See all - Disease index from A to Z

Magazine

Our featured pieces
News
Testimonials
Nutrition
Advice
Procedures & paperwork

Medications

Medications fact sheet
See all - Medication index from A to Z

Surveys

Ongoing surveys
The results of the surveys

Join now! Log in
  • Forums

    • Latest discussions
    • General discussions
    • See all - Forum index from A to Z
  • Conditions

    • Fact sheets
    • See all - Disease index from A to Z
  • Magazine

    • Our featured pieces
    • News
    • Testimonials
    • Nutrition
    • Advice
    • Procedures & paperwork
  • Medications

    • Medications fact sheet
    • See all - Medication index from A to Z
  • Surveys

    • Ongoing surveys
    • The results of the surveys
  • Home
  • Forums
  • General forums
  • Treatments for multiple sclerosis
  • Multiple Sclerosis Clinical Trials More Successful Than Other Diseases
 Back
Treatments for multiple sclerosis

Multiple Sclerosis Clinical Trials More Successful Than Other Diseases

  •  13 views
  •  1 support
  •  1 comment

avatar Gilda

Gilda

Community manager
Edited on 15/01/2016 at 11:43

Good advisor

avatar Gilda

Gilda

Community manager

Last activity on 03/02/2023 at 15:26

Joined in 2015


710 comments posted | 45 in the Treatments for multiple sclerosis group


Rewards

  • Good Advisor

  • Contributor

  • Messenger

  • Committed

  • Explorer

  • Evaluator


 View profileView  Add a friendAdd  Write
Clinical trials for multiple sclerosis (MS) therapies demonstrate a success rate that is nearly triple that of other diseases, with small molecules and novel drugs appearing superior, according to an analysis published in Multiple Sclerosis and Related Disorders.
Over the last 20 years, there has been a rapid increase in the number of available disease-modifying therapies (DMT) for MS.

“MS is a ‘best in class' disease area relative to other disease conditions when you look at the number of new drug approvals that have taken place and the fact that many represent very different mechanisms of action,” Jayson Parker, PhD, assistant professor at the University of Toronto Mississauga, told Neurology Advisor. “Within neurology this is simply not the case for conditions such as Alzheimer's disease, depression, or Parkinson's disease.”
 
In the current study, Dr Parker and colleagues aimed to highlight any specific risk factors for clinical trial failure of MS drugs by comparing clinical trial success rates. They collected data on Phase 1, 2, and 3 clinical trials from 1998 to January 2015 on drugs tested for MS and then compared the data to industry standard success rates.
Of the 53 distinct compounds that met inclusion criteria, 25 trials progressed and 5 compounds were FDA approved for MS during the study period. In all trial phases, MS clinical trials had a 27% success rate compared to an industry rate of 10%. Most of the clinical trials were conducted in a relapsing-remitting MS (RRMS) population (N=22), however those studied in a relapsing MS population were found to have a 100% phase III clinical trial success rate (N=3). The authors point out that there have been no successful phase III clinical trials exclusively studying patients with secondary-progressive MS (SPMS) or primary-progressive MS (PPMS).

There were more biologics being studied than small molecules (28 vs 24), however small molecules had a higher clinical trial success rate (31% vs 13%) than biologics (23% vs 32%) when compared to industry small molecules and biologics, respectively. Drugs studied for MS with a prior FDA approval for an alternative indication had a lower success rate than novel drugs.
“Our results suggest this prior approval history does not mitigate the risk of clinical trial failure,” Dr Parker said. “On the contrary, new drugs without any prior FDA approval history seem to carry less clinical trial risk in MS. Physicians should continue to embrace novel drugs with new mechanisms of action in this condition.”

“The best step for risk reduction is the use of biomarkers,” Dr Parker continued. “Physicians should push back on manufacturers and demand that biomarker use be explored in inclusion and exclusion criteria in phase 2 studies and be maintained into phase 3 if the data warrants.”

Neurology Advisor
Follow

Other groups...

All things Christmas
Carenity News
Feedback for Carenity
Fun and games
Good to know
How to use Carenity
Let's talk about COVID-19
Life beyond illness
News from the media
Procedures and Paperwork
Youth patients with chronic conditions

Give your opinion

Survey

What do you think about the Carenity Forum and community?

Survey

How do you use Carenity? Share your experience!

All comments

avatar Yank34

Yank34

Ambassador
15/01/2016 at 11:43

Good advisor

avatar Yank34

Yank34

Ambassador

Last activity on 02/07/2025 at 16:40

Joined in 2015


291 comments posted | 59 in the Treatments for multiple sclerosis group

17 of their responses were helpful to members


Rewards

  • Good Advisor

  • Contributor

  • Committed

  • Explorer

  • Evaluator

  • Friend


 View profileView  Add a friendAdd  Write

Thanks for sharing Gilda! As usual, you continue to be a wonderful source of info and support and sooooooooooooooo appreciate you!!!!

Ann x

See the signature

Ann


Multiple Sclerosis Clinical Trials More Successful Than Other Diseases https://www.carenity.co.uk/forum/other-discussions/your-opinion-on-multiple-sclerosis-treatments/multiple-sclerosis-clinical-trials-more-succes-735 2016-01-15 11:43:12

Give your opinion

Survey

What do you think about the Carenity Forum and community?

Survey

How do you use Carenity? Share your experience!

Articles to discover...

Screens and the brain: What are the risks of overuse and how can you protect yourself?

28/06/2025 | News

Screens and the brain: What are the risks of overuse and how can you protect yourself?

Women's health: Why is medical research still falling short?

21/06/2025 | News

Women's health: Why is medical research still falling short?

Can you train your brain to feel happier, scientifically?

14/06/2025 | Advice

Can you train your brain to feel happier, scientifically?

Cognitive behavioural therapy (CBT): A way to better live with your thoughts and emotions

09/06/2025 | News

Cognitive behavioural therapy (CBT): A way to better live with your thoughts and emotions

NHS - Get help with prescription costs

12/11/2019 | Procedures & paperwork

NHS - Get help with prescription costs

Diclofenac to become a prescription drug

21/01/2015 | News

Diclofenac to become a prescription drug

Opioids Causing Concerns, Problems for Chronic Pain Patients

14/10/2016 | News

Opioids Causing Concerns, Problems for Chronic Pain Patients

Do you have the winter blues?

21/10/2014 | News

Do you have the winter blues?

icon cross

Does this topic interest you?

Join the 500 000 patients registered on our platform, get information on your condition or on that of your family member, and discuss it with the community

Join now! Join now! Join now! Join now! Join now!

It’s free and confidential

Subscribe

You wish to be notified of new comments

 

Your subscription has been taken into account

Join now! Log in

About

  • Who are we?
  • The Carenity team
  • The Science and Ethics Committee
  • Contributors
  • Carenity in the news
  • Certifications and awards
  • Data For Good
  • Our scientific publications
  • Discover our studies
  • Editorial policy
  • Code of conduct
  • Our commitments
  • Legal notice
  • Terms of use
  • Cookies management
  • Contact
  • Carenity for professionals

Quick access

  • Health magazine
  • Search a forum
  • Learn about a condition
  • See medication reviews
  • List of forums (A-Z)
  • List of condition info sheets (A-Z)
  • List of medication fact sheets (A-Z)
  • Language flag fr flag de flag es flag it flag us

The www.carenity.co.uk website does not constitute or replace professional medical advice.